Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trial.
Brody JD, Jørgensen JM Dr, Belada D, Costello R, Trněný M, Vitolo U, Lewis DJ, Karimi YH, Sureda A, Andre M, Wahlin BE, Lugtenburg PJ, Jiang T, Karagoz K, Steele AJ, Abbas A, Wang L, Risum M, Cordoba R. Brody JD, et al. Among authors: karagoz k. Blood. 2025 Jan 10:blood.2024026830. doi: 10.1182/blood.2024026830. Online ahead of print. Blood. 2025. PMID: 39792928
Corrigendum to Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
Kanlikilicer P, Bayraktar R, Denizli M, Rashed MH, Ivan C, Aslan B, Mitra R, Karagoz K, Bayraktar E, Zhang X, Rodriguez-Aguayo C, El-Arabey AA, Kahraman N, Baydogan S, Ozkayar O, Gatza ML, Ozpolat B, Calin GA, Sood AK, Lopez-Berestein G. Kanlikilicer P, et al. Among authors: karagoz k. EBioMedicine. 2025 Jan;111:105486. doi: 10.1016/j.ebiom.2024.105486. Epub 2024 Dec 4. EBioMedicine. 2025. PMID: 39637523 Free PMC article. No abstract available.
Correction: Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U. Kurata K, et al. Among authors: karagoz k. Blood Cancer J. 2023 Feb 7;13(1):24. doi: 10.1038/s41408-023-00793-y. Blood Cancer J. 2023. PMID: 36746923 Free PMC article. No abstract available.
Prolyl-tRNA synthetase as a novel therapeutic target in multiple myeloma.
Kurata K, James-Bott A, Tye MA, Yamamoto L, Samur MK, Tai YT, Dunford J, Johansson C, Senbabaoglu F, Philpott M, Palmer C, Ramasamy K, Gooding S, Smilova M, Gaeta G, Guo M, Christianson JC, Payne NC, Singh K, Karagoz K, Stokes ME, Ortiz M, Hagner P, Thakurta A, Cribbs A, Mazitschek R, Hideshima T, Anderson KC, Oppermann U. Kurata K, et al. Among authors: karagoz k. Blood Cancer J. 2023 Jan 12;13(1):12. doi: 10.1038/s41408-023-00787-w. Blood Cancer J. 2023. PMID: 36631435 Free PMC article.
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma.
Gooding S, Ansari-Pour N, Kazeroun M, Karagoz K, Polonskaia A, Salazar M, Fitzsimons E, Sirinukunwattana K, Chavda S, Ortiz Estevez M, Towfic F, Flynt E, Pierceall W, Royston D, Yong K, Ramasamy K, Vyas P, Thakurta A. Gooding S, et al. Among authors: karagoz k. Blood. 2022 Oct 20;140(16):1816-1821. doi: 10.1182/blood.2022015909. Blood. 2022. PMID: 35853156 Free PMC article.
27 results